Pharma's Reputation In A Post-Fact World
Executive Summary
How should an industry built on expertise, evidence and facts adapt to a new, break-the-wheel era that’s had enough of the experts? Four points to act on before the Tweetstorm visits the C-suite.
You may also be interested in...
The New World Of Pharma – Markets, Messaging And The Flash Mob
Our look back at 2016 and at prospects for the year ahead plots a rush of often conflicting head and tail winds, all requiring unrelenting focus from the C-suite on what matters to preserving pharma's vital public license to operate. Events in the sales-leading US market remain the key driver of change and a test ground for managing the competitive and reputational challenges industry faces from a more restive – and powerful – customer base.
Pharma's Latest Davos Pledge: Sincere, Or Just Keeping Up Appearances?
Many hope the "dialogue of the deaf" between pharma and other healthcare stakeholders can be truly bridged by the industry's latest Davos declaration to collaborate in targeting chronic diseases of the poor.
Viz.ai: Precision Targeting Of Every Patient’s Medical “Moment Of Truth”
Viz.ai is making artificial intelligence real and ready with an algorithm-based detection and diagnostics platform that is beating the clinical clock in fighting stroke. The start-up is now focused on positioning its joined-up AI software as standard-setter for broader patient engagement with big pharma on everything from participation in clinical trials to launching the next generation of high-touch specialty medicines.